Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. Other serious side effects include serious allergic reactions, tears in the stomach or intestines, and …

Upadacitinib, also known as Rinvoq®, is a treatment for moderate to severe atopic eczema (also known as atopic dermatitis) in adults and children aged 12 years and older.

Oct 16, 2025 · Rinvoq is also approved to psoriatic arthritis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic …

Rinvoq (upadacitinib) is an oral JAK1 inhibitor approved by the FDA for adults and adolescents aged 12+ years with moderate to severe atopic dermatitis whose disease is not adequately …

Dec 19, 2023 · Rinvoq has been found to be safe at two doses—15 mg and 30 mg—in three clinical trials that included over 2,500 people in total. However, side effects are possible, and …

RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately …

Sep 8, 2025 · Rinvoq (upadacitinib) is strongly recommended for adults with moderate to severe atopic dermatitis, but only after failure of other systemic therapies (including biologics) or when …

For adults and children 12+ years with moderate to severe eczema (atopic dermatitis) that did not respond to previous treatment and their eczema is not well controlled using other pills or …

Jul 8, 2024 · Rinvoq is an oral prescription medication containing the active ingredient upadacitinib. It can be used to treat symptoms of eczema, rheumatoid arthritis, psoriatic …